|
APTX expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.76850000199735E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.36729999999918E-06 |
| Normal-vs-Stage2 |
2.118000E-02 |
| Normal-vs-Stage3 |
7.37249999938072E-08 |
| Normal-vs-Stage4 |
9.99570004545092E-09 |
| Stage1-vs-Stage2 |
3.249000E-01 |
| Stage1-vs-Stage3 |
1.055770E-01 |
| Stage1-vs-Stage4 |
2.399600E-02 |
| Stage2-vs-Stage3 |
4.958200E-02 |
| Stage2-vs-Stage4 |
1.894310E-02 |
| Stage3-vs-Stage4 |
3.634800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.88000000514543E-08 |
| Normal-vs-AfricanAmerican |
2.92560000003661E-06 |
| Normal-vs-Asian |
2.200600E-03 |
| Caucasian-vs-AfricanAmerican |
3.253200E-01 |
| Caucasian-vs-Asian |
1.024630E-01 |
| AfricanAmerican-vs-Asian |
4.141700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.23200000037949E-07 |
| Normal-vs-Female |
6.47659999963857E-07 |
| Male-vs-Female |
2.989800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.64250000003852E-06 |
| Normal-vs-Age(41-60Yrs) |
6.33840000485719E-08 |
| Normal-vs-Age(61-80Yrs) |
9.4599000000084E-07 |
| Normal-vs-Age(81-100Yrs) |
1.058300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.372000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.296600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.442000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.228400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.591400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.422000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.845600E-02 |
| Classical-VS-Follicular |
9.356000E-02 |
| Classical-VS-Other |
4.968000E-01 |
| Classical-VS-Normal |
1.33569999505312E-08 |
| Tall-VS-Follicular |
6.699500E-03 |
| Tall-VS-Other |
9.292400E-01 |
| Tall-VS-Normal |
8.45199998877888E-09 |
| Follicular-VS-Other |
3.460200E-01 |
| Follicular-VS-Normal |
1.096230E-02 |
| Other-VS-Normal |
4.339100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.55520000003173E-06 |
| Normal-vs-N1 |
3.85989999962533E-07 |
| N0-vs-N1 |
5.840200E-02 |
|
|
